
sep pm et
summari largest retail drug chain term revenu compani oper
drug store throughout puerto rico
price-to-earnings oper ep
risk assess reflect compani strong
market share posit rel stabl retail
drug industri partli off-set growth non-tradit
competitor potenti advers legisl
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep pm stock trade
see sale grow fy aug
fy reflect
acquisit nearli
store march compstore sale
like grow fy
fy reflect brand drug price inflat
market share gain rise demand
age popul partial off-set shift
focus margin expans rather
grow volum despit benefit
ebitda margin like widen
fy remain flat fy
benefit cost cut improv
purchas favor gener
merchandis mix off-set increas
benefit million cost cut
anoth million synergi
acquisit store end
estim reduct share
count due share repurchas benefit
lower tax rate look fy
oper ep rise nearli
forecast ep growth fy
exclud one-tim item period
compani complet acquisit
store march
scale think import
help improv drug purchas power
believ deal also provid turnaround
growth opportun under-perform
store addit remain
cautiou underestim power
disrupt retail
pharmaci view drug purchas
relationship signific local consum
touch point provid high barrier
penetr intermedi term
risk recommend target price
follow integr recent acquisit
higher-than-expect competit
target price assum
ev/ebitda three-year
averag forward ev/ebitda
assum fy ebitda billion see
valuat pressur increas headlin risk
particularli took larger roll
on-line pharmaci agre acquir on-line
retail pillpack june
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview one largest drug store chain world
base sale store count compani founder charl rudolph walgreen sr purchas
one busiest drug store chicago south side transform construct ice cream
fountain featur brand ice cream ice cream fountain forerunn
famou walgreen soda fountain becam main attract custom
peopl line buy product wag invent earli milkshak
compani launch loyalti program balanc reward septemb million
member august million august
market profil walgreen oper one largest drug store chain world base sale
gener billion sale fiscal year aug compani fill million
million adjust equival prescript fiscal year
million fiscal year account retail prescript drug market revenu
medicaid repres us pharmaci divis sale fiscal year medicar part
plan contribut us pharmaci sale fiscal year compani also one
largest oper drug store unit basi oper locat state
district columbia puerto rico guam
impact major develop octob compani agre acquir rite aid corpor
oper drug store state district columbia billion cash per
share follow regulatori concern compani reach new agreement acquir
store receiv regulatori approv septemb complet acquisit
store march expect achiev million annual synergi within four year
close deal anoth million cost save end fiscal year think
achiev
septemb compani began new brand gener drug distribut agreement
one north america largest pharmaceut servic compani may
wag extend agreement addit three year januari compani
own outstand share elect one member board director august
acquir addit million share open market design
second member abc board director
august compani acquir interest allianc boot lead intern pharmaci
store oper pharmaci wholesal drug distributor suppli
pharmaci countri billion cash stock august walgreen exercis
option acquir remain interest allianc boot gbp billion cash
million share wag stock deal complet decemb
walgreen achiev goal billion allianc boot annual synergi third quarter fiscal
year compani think signific short- long-term synergi opportun
gener procur save revenu gener procur save includ prescript
drug counter front-end non-pharmaci purchas indirect spend cost save revenu
opportun includ introduc allianc boot product brand drug store oper walgreen
addit revenu synergi may gener share best practic particularli
pharmaci oper health well servic logist
april compani acquir new york-bas drug store chain duan read affili oak
hill capit partner total enterpris valu billion cash acquisit includ drug
store two distribut center acquisit provid compani lead market share posit
new york citi largest drug store market
financi trend compani complet billion share repurchas program fiscal year
ad anoth billion author octob complet prior plan
june board author addit billion share repurchas program expect
compani complet fy end expect maintain dividend pay-out ratio
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
gener drug purchas
entiti red oak sourc
corp either directli
expect near-term advers
impact potenti chang health care
legisl long-term demand would
restrict peopl lose health care
coverag also expect prescript revenu
growth somewhat limit next
month due convers brand
drug lower-pr gener drug
near-term peak benefit sale
gener drug occur
addit brand drug lost patent
protect also see in-stor health clinic
offer increasingli help drive store
traffic prescript front-end sale
servic expand
year date april
declin
industri index declin compar
increas think
under-perform reflect increas
industri drug reimburs pressur
slow in-stor traffic trend due increas
competit despit increas demand
expand health care coverag
neutral fundament outlook
drug retail sub-industri next month
see sale continu benefit
increas demand age babi boomer
see margin benefit increas gener drug
purchas power improv sale leverag
howev see margin expans limit
intens drug reimburs pressur
increas competit non-tradit
compani within retail drug industri
well posit view benefit
increas prescript drug usag
develop privat loyalti card
program prescript volum like rise
age babi boomer nearli
util prescript drug addit
reflect conveni locat close
consum home retail drugstor better
posit take market share
non-tradit competitor expans
loyalti card program like help support
increas basket size traffic reflect
person shop experi
custom also loyalti program like
help support retail margin due improv
market promot spend effici
drug retail like experi
increas margin pressur lower
drug reimburs level believ
reflect unfavor shift consum mix
consum shift toward larg third payer
plan medicaid medicar
increas focu health plan reduc
health care cost help off-set
pressur expect drug chain continu
seek reduc drug acquisit cost
increas scale exampl walgreen
benefit improv purchas follow
complet acquisit rite
aid store march estim
base index
five-year market price perform sep
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target price ev/ebitda
line peer assum complet rad merger albertson
end calendar keep fy feb ep estim initi
fy ep feb-q adjust loss per share vs loss
wider estim reflect recent asset sale store sale
declin line expect hurt exclus health
plan pharmaci network intens non-pharmaci competit posit
view stabil drug reimburs rate feb-q
sourc signific margin pressur recent year expect margin benefit
reduc gener drug purchas cost compani leverag new
sourc relationship follow
complet sale store march /joseph agnes
et cfra keep buy opinion share walgreen boot
allianc trim target price-to-earnings
lower end rang fy aug ep estim
see valuat hurt intens drug reimburs
pressur partial off-set benefit increas scale lift fy
ep estim feb-q ep vs
estim compar store sale growth estim
benefit pharmaci market share gain see non-pharmaci sale
pressur priorit margin expans volum growth /joseph
analyst research note compani news
et cfra add compani high-qual capit
appreci portfolio ba posit thrive
view commerci defens servic address market
expect grow trillion next year airplan order flow
deep backlog year product suggest durabl revenu
growth profil remain intact see step-up
defens busi continu benefit
favor budget backdrop higher contract volum look ahead think
global air traffic demand trend grow servic busi could help
buffer cyclic trend past suppli chain constraint linger
previous implement recoveri continu take hold think could
restor normal product rate quicker expect think
plan mid-teen oper margin achiev
given focu lean cost product line effici ba
replac high-qual capit appreci
hold buy trim target price
valu share ev/ebitda multipl fy aug
ebitda estim billion discount three-year averag
forward ev/ebitda think warrant risk
intensifi competit pressur on-go pressur drug
reimburs model partli offset risk see strong synergi
opportun form acquisit store march
maintain fy ep estim trim fy ep forecast
given on-going headlin risk could aris amazon
larger role pharmaci market think rel valuat less
attract follow increas share sinc begin
juli recent share price appreci driven sole multipl
expans forward ev/ebitda expand begin
juli today consensu earn remain flat /matthew
et cfra keep buy opinion share walgreen boot
allianc rais target
assum ev/ebitda near low end compani five
year trade rang ebitda billion continu believ
valuat pressur neg headlin risk amazon expand pharmaci
offer howev believ well posit benefit larg
gener specialti drug purchas scale believ difficult
amazon replic outsid partnership larg drugstor
pharmaci benefit manag particip also believ well posit
benefit store provid local consum touch point remain
attract consum seek immedi relief acut healthcar
condit nevertheless see ep growth remain pressur on-going
industri drug reimburs pressur support growth
feder state govern health program medicaid medicar
narrow prescript drug network /joseph agnes
et cfra keep buy opinion share walgreen boot
allianc inc lower target
assum ev/ebitda near low end rang
see valuat pressur increas headlin risk particularli
take larger roll on-line pharmaci agre
acquir on-line retail pillpack today remain cautiou
underestim power disrupt retail pharmaci view
drug purchas scale larg specialti drug busi pbm relationship
signific local consum touch point provid high barrier
penetr report may-q adjust ep vs
estim share count declin believ weak share
today increas likelihood aggress use new
billion repurchas approv compar store sale growth
estim see non-pharmaci sale remain pressur
priorit margin expans volum growth /joseph agnes
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
